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1. Introduction 
Drug-eluting stents (DES) substantially reduce restenosis compared with bare metal stents 
and represent a significant advance in percutaneous coronary interventions (PCIs). 
Accordingly, DES have been rapidly adopted into practice and are currently used in the vast 
majority of PCI procedures. As PCIs for more complicated lesions increase, various 
complications, such as stent thrombosis, fracture, dissection or perforation, are also increase. 
For example, PCIs for patients who have chronic total occlusion increase and these patients 
tend to have more risk factors like diabetes mellitus, hypertension, dyslipidemia, and 
previous myocardial infarction and also have multi-vessel diseases and have decreased left 
ventricular ejection fraction. If major procedure-related complications were developed in 
these high risk patients, it may leads to fatal results. So it is important to understand 
possible complications of PCIs and eliminate potential risk factors before procedures. 
1.1 Stent fracture 
Drug-eluting stents (DES) have proven very effective in reducing restenosis by suppressing 
neointimal hyperplasia. However, potentially serious complications such as in-stent 
restenosis and thrombus still occur. Stent fracture has been identified as a possible 
contributor to these adverse outcomes. A number of risk factors for the development of stent 
fracture have been described, although a detailed analysis of the angiographic factors 
predisposing to stent fracture is lacking. 
1.2 Incidence and definition 
Stent fracture is defined as the cases where the linear or curvilinear connections of stent 
struts are interrupted and areas of the stented segment are uncovered by stent struts visible 
on coronary angiography. The incidence of stent fracture is reported in 0.8-7.7% of cases.1-8 
However, because of limited sensitivity of angiography to detect fracture, its true incidence 
is still unknown. In a recent report analyzed from autopsy findings, stent fracture was 
observed in 29% of total patients.9 So, the real incidence of stent fracture is assumed to be a 
little higher than what has been clinically reported. Stent fracture from patients treated with 
Cypher stents is more frequently observed than in cases of Taxus stents. The incidence of 
stent fracture of Cypher stent was 1.3% in the SIRIUS trial,9 compared to 0.58% incidence 
with the Taxus stent is in the Taxus IV/V/VI trials. Stent fracture has previously been 
recognized in noncoronary vessels, especially in the superficial femoral and popliteal arteries 
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and with bare-metal stents in saphenous vein grafts.10,11 Because old classifications of stent 
fracture are originated from in cases of femoropopliteal arteries, Popma et al. suggested a more 
detailed new classification specially designed for coronary arteries (Figure 1, Table 1).12 
1.3 Predictors and possible mechanisms 
Stent fractures in the bare-metal stent era might be overlooked and masked due to the 
diffuse tissue overgrowth within the stented segment. Because drug-eluting stents can 
suppress neointimal hyperplasia more effectively thereby stent fracture may now be more 
obvious in the very localized lesions bordered by segments with no evidence of neointima.13 
As already mentioned, among DESs, Cypher stents showed more frequent stent fractures 
compared to Taxus stents. The inter-strut angles of the Cypher stent which has a closed-cell 
design, were significantly smaller than Taxus stent which has an open-cell design.14 The 
different stent strut design should be considered as a key mechanism of Cypher stent 
fracture. To maintain smaller inter-strut angles and a more regular strut distribution, there 
must be higher shear forces on the struts of Cypher stent. Therefore the closed-cell designed 
Cypher stent may be more prone to fracture when shear forces are beyond its flexibility. It 
seems that stent fractures are rare in newer generation stents such as Xience V or Eendeavor 
stents. Stent fractures most frequently occur in the right coronary artery followed by the left 
anterior descending artery and finally the left circumflex artery. The predisposition of the 
right coronary artery for stent fracture is possibly attributed to the vessel anatomy, due to 
the excessive tortuosity, angulation, or change of angulation after stent implantation. Vessel 
movement throughout the cardiac cycle creates flexion, stretching, and torsion forces, 
creating hinge points and can lead to mechanical fatigue and fracture.2 Procedure related 
contributing factors are longer and more angulated lesions, lesions that are ostial in location 
with more proximal tortuosity, calcification, total occlusion, stent overlap, stenting in 
saphenous vein grafts, and overstretching of the stents with high pressure.12  
 
Fig. 1. Definitions used for stent fracture 
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Classification Current report Allie et el Scheinert et al 
Type 0 No strut fracture - - 
Type I Single strut fracture or 
gap between struts 
greater than 2 times 
expanded cell diameter 
Single strut fracture 
only 
Minor-single strut 
fracture 
Type II Multiple strut fracture 
with V-form division of 
the stent 
Multiple single stent 
fractures occurring at 
different sites 
Moderate-fracture >1 
strut 
Type III Complete transverse 
stent fracture without 
displacement of 
fractured fragments 
more than 1 mm during 
the cardiac cycle 
Multiple single stent 
fractures resulting in 
complete transverse 
linear fracture but 
without stent 
displacement 
Severe-complete 
separation of stent 
segments 
Type IV Complete transverse 
stent fracture with 
abundant movement 
and displacement of 
fractured fragments of 
more than 1 mm during 
the cardiac cycle 
Complete transverse 
linear type III 
fracture with stent 
displacement 
 
 
 
- 
Table 1. Definitions used for stent fracture12 
1.4 Clinical implications 
The complications observed with DES fracture include in-stent restenosis, target lesion 
revascularization, stent thrombosis, myocardial infarction, stent-related aneurysm, and 
sudden death. Lee et al. observed binary restenosis in six out of 10 patients (60%) with stent 
fracture and one patient had stent thrombosis.5 Local mechanical irritation of the vessel can 
occur from fractured stent struts, which may result in inflammation and neointimal 
hyperplasia. Restenosis could also reflect decreased local drug availability secondary to 
distortion of the stent architecture and polymer coating.13 Exposure of a free metal strut 
protruding into the vessel lumen could trigger platelet activation and resultant stent 
thrombosis. Acute myocardial infarction and sudden death can develop from fracture-
related stent thrombosis. 
1.5 Diagnosis and treatment 
Usually stent fracture can be diagnosed by conventional fluoroscopy or follow-up coronary 
angiography. If the diagnosis is obscure, Intravascular Ultrasound (IVUS), Multi-Detector 
Computed Tomography (MDCT), or Optical Coherence Tomography (OCT) can be helpful. 
Because recently developed stents tend to have thinner struts and less radiopacity, the 
diagnosis of stent fracture tends to difficult. Unfortunately, there is no consensus of the 
treatment of stent fracture. It depends on whether or not there is restenosis and its related 
symptoms. 
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2. No-reflow phenomenon 
The phenomenon of no-reflow is defined as inadequate myocardial perfusion through a 
given segment of the coronary circulation without angiographic evidence of mechanical 
vessel obstruction.15 The underlying cause of no-reflow is microvascular obstruction, which 
may be produced by various mechanisms. The concept of no-reflow was first described in 
experimental models in 196616 and then in the clinical setting of reperfusion after myocardial 
infarction in 1985.17 No-reflow has been documented in ≥30% of patients after 
thrombolysis18 or mechanical intervention for acute myocardial infarction. The prevalence is 
variable, ranging from 5% up to 50%, according to the methods used to assess the 
phenomenon and to the population under study.   
A series of consistent data has clearly shown that no-reflow has a strong negative impact on 
outcome, negating the potential benefit of primary percutaneous coronary intervention 
(PCI).19,20 Indeed, patients with no-reflow exhibit a higher prevalence of: 1) early post-
infarction complications (arrhythmias, pericardial effusion, cardiac tamponade, early 
congestive heart failure); 2) left adverse ventricular remodeling; 3) late repeat hospital stays 
for heart failure; and 4) mortality.  
Therefore, it is important to prevent and effectively treat the no-reflow phenomenon during 
PCI to achieve an optimal outcome. 
2.1 Historical overview 
The term no-reflow was first used by Majno and colleagues21 in the setting of vertebral 
ischemia in 1967. This phenomenon was initially described by Krug et al.16 during induced 
myocardial infarction in the canine model in 1966 and again by Kloner et al.15 in 1974 in 
which it occurred for 90 min after temporary epicardial coronary artery occlusion followed 
by reperfusion. Electron microscopic examination showed severe myocardial capillary 
damage with loss of pinocytonic vesicles in the endothelial cells, endothelial blisters or blebs 
and endothelial gaps with neutrophil infiltration. Intraluminal capillary plugging by 
neutrophils and/or microthrombi with myocardial cell swelling was also noted. Galiuto et 
al.22 with sequential measurements of myocardial perfusion by myocardial contrast 
echocardiography, have recently shown that in humans no-refow detected 24 h after 
successful PCI spontaneously improves over time in approximately 50% of patients. Thus, no-
reflow can be categorized as sustained or reversible. Sustained no-reflow is probably the result 
of anatomical irreversible changes of the coronary microcirculation, whereas reversible no-
reflow is the result of functional and thus, reversible, changes of the microcirculation.  
In humans, no-reflow is caused by the variable combination of 4 pathogenetic components: 
1) distal atherothrombotic embolization; 2) ischemic injury; 3) reperfusion injury; and 4) 
susceptibility of the coronary microcirculation to injury. 
1. Distal embolization 
Emboli of different sizes can originate from epicardial coronary thrombus and from fissured 
atherosclerotic plaques, in particular during primary PCI.23 Large emboli (>200μm diameter) 
can obstruct pre-arterioles, causing infarctlets. Experimental observations have shown that 
myocardial blood flow decreases irreversibly when microspheres obstruct more than 50% of 
coronary capillaries.24  
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2. Ischemia-related injury 
Changes in endothelial cells, visible after prolonged ischemia, are represented by 
endothelial protrusions and membrane-bound bodies, which often fill the capillaries up to 
luminal obliteration. Furthermore, large endothelial gaps with extravascular erythrocytes 
are common.25 
3. Reperfusion-related injury 
A massive infiltration of the coronary microcirculation by neutrophils and platelets occurs at 
the time of reperfusion.25,26 Reintroduction of neutrophils in post-ischemic myocardium 
results in their activation, with subsequent adhesion to the endothelial surface and 
migration in the surrounding tissue. Activated neutrophils, in turn, release oxygen free 
radicals, proteolytic enzymes, and pro-inflammatory mediators that can directly cause tissue 
and endothelial damage. Neutrophils also form aggregates with platelets that plug 
capillaries, thus mechanically blocking flow.27,28 Finally, vasoconstrictors released by 
damaged endothelial cells, neutrophils, and platelets contribute to sustained 
vasoconstriction of the coronary microcirculation.29 Tumor necrosis factor-alpha expression 
is induced by reperfusion, and can impair endothelium-dependent coronary flow reserve.30 
Interleukin-1β also has recently been associated with ischemia-reperfusion injury, because 
interleukin-1β knockout animals exhibit marked reduction of ischemic induced 
inflammation.31 Selectin expression on cell surfaces is also important for mechanical 
plugging of the microcirculation.32 Finally, the balance between nitric oxide and superoxide 
is tipped in favor of superoxide within minutes of reperfusion of ischemic tissues, due to 
increased production of xanthine oxidase by neutrophils, endothelial cells, and cardiac 
myocytes, which leads to an exacerbation of the inflammatory state.33  
Reperfusion might also cause irreversible injury to myocytes.34 During ischemia there is an 
increase of the intracellular sodium (Na+) content due to accumulation of hydrogen (H+), 
which is exchanged by the Na+/H+ exchanger. The subsequent exchange of doubly charged 
positive calcium ion (Ca++) with Na+ by the sarcolemmal Na+/Ca++ exchanger produces a 
calcium overload that triggers uncontrolled hypercontraction and stimulates opening of the 
mitochondrial permeability transition pore (m0PTP), which further enhances calcium 
overload. Furthermore, Na+ extrusion trough Na+/potassium (K+) adenosine triphosphate 
(ATP)-ase is impaired and together with Ca++ accumulation leads to myocyte cell swelling, 
which contributes to subsequent rupture of the cell membrane when the extracellular 
osmolality is rapidly normalized by reperfusion. Of note, cyclosporine, which blocks the m-
PTP, has been recently shown to reduce infarct size by 20% when administered 
intravenously in patients undergoing primary PCI.35 Finally, ischemic pre-conditioning 
might also reduce infarct size by blockade of m-PTP.36 
Natriuretic peptides might modulate ischemia-reperfusion injury. Atrial natriuretic peptide 
might suppress the rennin-angiotensin-aldosterone system and endothelin (ET)-1 that 
increase infarct size, microvascular obstruction, and cardiac remodeling.37 
4. Individual predisposition of coronary microcirculation to injury 
In humans, no-reflow is occasionally observed during elective procedures,38 whereas it can 
be absent after primary PCI in patients with acute myocardial infarction. In particular, 
diabetes and hypercholesterolemia has been associated with impaired microvascular 
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reperfusion by enhancing endothelial oxidative stress.39,40 Pre-conditioning by using 
nicorandil seems to have a beneficial effect on microvascular function.41  
2.2 Diagnosis 
1. Coronary angiography 
Reduced coronary flow after primary PCI (TIMI flow 0 to 2) is associated with worse 
outcome than normal (TIMI 3) flow, even when no significant epicardial obstruction 
remains.42 More sensitive markers of tissue perfusion have now been identified and provide 
prognostic information beyond that of TIMI flow grade. The TIMI frame count assesses the 
number of angiographic frames required for the contrast medium to reach standardized 
distal landmarks of the coronary tree, and the myocardial blush grade (MBG) is a 
quantitative assessment of myocardial contrast density. The MBG is scored on a scale of 0 to 
3, with higher scores indicating better perfusion. An MBG 0 to 1, suggestive of no-reflow, is 
observed in as high as 50% of patients with TIMI flow grade 3.43 Taken together, 
angiographic no-reflow can be defined as a TIMI flow grade <3 or 3 with an MBG 0 to 1. 
2. Electrocardiography 
Rapid ST-segment resolution defined as a reduction of ≥50% in the ST-segment elevation 
index is highly specific (91%) for myocardial reperfusion (or the absence of no-reflow on 
myocardial contrast echocardiography) although less sensitive (77%).44  
3. Myocardial contrast echocardiography (MCE) 
Lack of intramyocardial contrast opacification is due to microvascular obstruction; thus, it 
represents the extent of no-reflow.45 In the AMICI study, the extent of no-reflow at MCE was 
demonstrated to be the best predictor of adverse left ventricular remodeling after acute 
myocardial infarction, being superior to ST-segment resolution and to MBG among patients 
exhibiting TIMI flow grade 3.20 
4. Cardiac magnetic resonance imaging 
No-reflow can be diagnosed as: 1) lack of gadolinium enhancement during first pass; and 2) 
lack of gadolinium enhancement within a necrotic region, identified by late gadolinium 
hyperenhancement.46 
2.3 Prevention and treatment (Figure 2) 
1. Distal embolization 
No specific technique is currently recommended in guidelines to prevent distal embolization 
during primary PCI. Direct stent implantation, by avoiding balloon-induced thrombus 
fragmentation and by entrapping the atherothrombus under the stent struts, has been 
suggested as a possible technique to reduce distal embolization in a specific subset of patients 
i.e. those with good distal visualization of the infarct-related artery after guidewire passage.47 
A more promising technique is the use of thrombectomy and distal filter devices. Although 
distal filter devices did not improve early or late prognosis compared with standard 
primary PCI, thrombectomy performed with a simple manual aspiration catheter revealed 
improved myocardial reperfusion and significantly reduced no-reflow.48 A recent large trial 
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by Svilaas et al.49 confirmed the improvement of reperfusion associated with manual 
thrombus-aspiration as compared with standard primary PCI showing a strikingly lower 
mortality at 12-month follow-up.50 So, it is suggested that manual thrombus aspiration 
should be used in the setting of primary PCI, particularly in patients with a high thrombus 
burden.51 
2. Ischemia-related injury 
Strategies aimed at reducing pain onset-to-balloon time might reduce no-reflow by 
decreasing total ischemic time. Drugs known to reduce myocardial oxygen consumption 
and consequently the severity of ischemia and improve myocardial perfusion include 
carvedilol, fosinopril, and valsartan.52,53 
3. Reperfusion-related injury 
Intracoronary nitroglycerin is usually suggested as the first-line agent, mainly to reverse 
epicardial vessel spasm, even if the blood pressure is reduced. Theoretically, nitroglycerin 
should have little impact on arteriolar tone and hence on no-reflow since physiologically it 
produces little effect in the microvasculature.  
Patients at high risk of no-reflow can be treated with drugs such as glycoprotein IIb/IIIa 
antagonists, adenosine, nicorandil, and nitroprusside aimed at counteracting endothelial, 
platelet, and neutrophil activation.  
 
Fig. 2. Therapies of no-reflow targeted to main pathogenetic mechanisms 
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Among glycoprotein IIb/IIIa antagonists, abciximab has been found to improve myocardial 
perfusion when started during primary PCI and infused for 12 h thereafter. Interestingly, 
intracoronary abciximab has been proven to be superior to intravenous abciximab in 
patients treated by primary PCI.54 Adenosine is an endogenous purine nucleoside that 
decreases arteriolar resistance and activates intracellular cardioprotective signaling 
pathways. Its mechanism of action may involve opening ATP-sensitive potassium channels 
(KATP), inhibition of neutrophil migration, prevention of superoxide generation, or blockade 
of coronary endothelin release. Nitroprusside is a nitric oxide donor that does not depend 
on intracellular metabolism to derive nitric oxide, with potent vasodilator properties. 
Nicorandil is a hybrid of a KATP opener and nitrate and may prevent reperfusion injury by 
blocking the mitochondrial permeability transition pore. Verapamil is a calcium-channel 
blocker that has several beneficial effects in the setting of no-reflow in addition to 
attenuation of microvascular spasm. Varapamil may also inhibit platelet aggregation and 
thrombus formation in the microvasculature and may have a direct effect on calcium flux 
across the sarcolemmal membrane or within intracellular compartment that could protect 
reversibly injuried myocytes. 
3. Coronary artery perforation and cardiac tamponade 
Coronary artery perforation complicating percutaneous coronary intervention (PCI) occurs 
in 0.1-3.0% of cases. Perforation with balloon angioplasty or stenting is rare, occurring in 
0.1% of cases. However, when ablation devices, such as rotablator, directional coronary 
atherectomy, transluminal extraction catheter, and excimer laser, are used, the frequency is 
substantially higher than with balloon angioplasty or stents, occurring up to 3.0%.55 
Recently, the use of ablation devices in PCI has tended to decline. Instead, procedures for 
more complex lesions including calcification, severe angulation, and chronic total occlusion 
have increased. To treat these complex lesions, stiffer and hydrophilic wires are necessary 
and high pressure for balloon dilatation is needed. Increasing numbers of procedures using 
glycoprotein IIb/IIIa inhibitors is also contributing to the fact that coronary artery 
perforation still occurs.  
3.1 Classification 
The Ellis classification depends on angiographic findings is most widely used (table 2).55  
 
Type I Extraluminal crater without extravasation  
Type II Pericardial or myocardial blush without contrast jet extravasation 
Type III Extravasation through frank (>1 mm) perforation 
Cavity Perforation into an anatomic cavity chamber, spilling coronary sinus, etc 
Table 2. Perforation Classification 
3.2 Risk factors 
Many factors are involved in coronary perforation during PCI. Related risk factors can be 
divided into patient-related, vessel-related, and procedure-related factors.56 Patients-related 
factors are old age, hypertension, PCI for unstable angina or non-ST segment elevation 
www.intechopen.com
 
Complications of Coronary Intervention 
 
55 
myocardial infarction.57 Vessel-related factors are ACC/AHA type C lesions, calcified 
lesions, and chronic total occlusion lesions.3 Procedure-related factors include use of stiff 
hydrophilic wires, device oversizing, use of atheroablative devices. One observational study 
reports that 87% of perforation due to guidewires is attributed to hydrophilic wires.58 In case 
of rotational atherectomy use, if lesions are eccentric, lesion length are >10cm, or lesions are 
very tortuous, the risk of perforation is high.  
3.3 Symptoms and signs 
If coronary perforation is develop, usually patients feel severe chest pain. In addition, 
nausea, dizziness, and vomiting can occur. The heart rate can rise suddenly, blood pressure 
can drop and if cardiac tamponade happens, an increase of central venous pressure with 
neck vein engorgement develops. Sustained ST-segment elevation or depression can be 
observed even though coronary balloons are deflated.  
3.4 Diagnosis 
The diagnosis of coronary artery perforation is not difficult by coronary angiography. If 
cardiac tamponade is suspected, then echocardiography is very useful. Sometimes 
perforation can occur 12-48 h later after PCI, if vital signs become unstable and serum 
hemoglobin and hematocrit levels decrease, cardiac tamponade must be suspected and 
urgent echocardiography should be performed. 
3.5 Clinical outcomes and prognosis 
Complications related to coronary artery perforation are diverse and depend on the degree 
of perforation. It has been reported that in cases of perforation, myocardial infarction can 
occurs in 13-34%, emergency coronary artery bypass graft in 11-39%, cardiac tamponade in 
12-31%, and mortality in 7.6-19%.59-61 The degree of perforation is a important marker to 
predict the late prognosis. Ellis classification type I perforation has a clinically good 
prognosis in 60% and it is rare that type II perforation has a poor prognosis. However, type 
III perforation reveals high major adverse events rate.55,62 
3.6 Treatment 
Generally, guidewire-related perforation does not cause grave results except with 
concomitant use of glycoprotein IIb/IIIa inhibitors. However, perforation due to balloon, 
atherectomy devices, or laser can produce hemopericardium or hemodynamic collapse.  
1. Prolonged balloon inflation 
The most important thing to stop bleeding is prolonged balloon inflation at the perforation 
site at least for 10-15 min at 2-6 atm. If bleeding does not stop, a perfusion balloon catheter 
can be used for 15-45 min inflated at low pressure. This prolonged balloon inflation and 
timely pericardiocentesis can avoid surgical treatment in patients with Ellis type I perforation.  
2. Stent 
In some cases, a polytetrafluoroethylene(PTFE)-covered stent is effective. Rarely, one or 
more conventional stent (bare metal or drug-eluting stent) implantation can be considered. 
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3. Pericardiocentesis  
If perforation is suspected, echocardiography should be performed and if hemopericardium 
is confirmed, pericardiocentesis should be performed immediately. An indwelling pericardial 
catheter should be maintained for 6-24 h and echocardiography should repeated every 6-12 h. 
4. Management of anticoagulation 
When perforation occurs, anticoagulation should be maintained to prevent thrombus 
formation. However, if perforation happens after use of atherectomy or laser, it is 
recommended that protamine sulfate should be administrated intravenously in order to 
partially reverse the effect of heparin. If contrast leakage is sustained despite prolonged 
balloon inflation, repeated balloon inflation should be performed; meanwhile the dosage of 
protamine sulfate should increase under activated clotting time monitoring.  
Glycoprotein IIb/IIIa inhibitors must be stopped. The effect of abciximab can be reversed 
after platelet transfusion of 6-10 units, but there are not any known antidotes for eptifibatide 
or tirofiban.  
 
Fig. 3. Management algorithm of coronary artery perforation  
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5. Embolization 
In case of small vessel size or distal location, limited involved myocardium, chronic total 
occlusion, or situation where surgery is unavailable, embolization using coils or gelfoam can 
successfully occlude the perforation.    
6. Surgical treatment 
If the perforation is severe, with hemodynamic instability or perforation is sustained despite 
nonsurgical management, emergency surgery is necessary. 
4. Coronary dissection and acute closure 
4.1 Angiographic definition 
Dissection is defined as disruption of an arterial wall resulting in splitting and separation of 
the intimal (or subintimal) layers. 
 
Feature Definition 
Abrupt Obstruction of contrast flow (TIMI 0 or 1) in a dilated segment with 
 closure previously documented anterograde flow 
Ectasia A lesion diameter greater than the reference diameter in one or more areas 
Luminal 
irregularities 
Arterial contour that has a saw-toothed pattern consisting of opacification 
but  not fulfilling the criteria for dissection or intracoronary thrombus 
Intimal flap A discrete filling defect in apparent continuity with the arterial wall 
Thrombus Discrete, mobile angiographic filling defect with or without contrast staining 
 Dissection   
A Small radiolucent area within the lumen of the vessel 
B Linear, nonpersisting extravasation of contrast material 
C Extraluminal, persisting extravasation of contrast material 
D Spiral-shaped filling defect 
E Persistent lumen defect with delayed anterograde flow 
F Filling defect accompanied by total coronary occlusion 
Dissection, 
 length(mm) 
Measure end to end for type B through F dissections 
Dissection, 
staining 
Persistence of contrast within the dissection after washout of contrast 
material from the remaining portion of the vessel 
Table 3. Standardized criteria for postprocedural lesion morphology63,64 
4.2 Pathogenesis and incidence of coronary dissection 
Intima-media cracks and medial dissection can be developed by balloon injury and if 
dissection involves the adventitia layer, narrowing of the lumen can occur.65 In NHLBI 
classification, coronary dissection occurs in 32-41% of total balloon procedures. If the lumen 
narrows >50% or the length of dissection is >10mm, the risk of abrupt vessel closure increases.  
In the modern PCI era, where coronary dissection can be promptly resolved by stent 
implantation, clinically significant dissection is reported only 1.7%. Residual dissection 
increases the risk of post procedure MI, emergency CABG, and stent thrombosis and 
mortality also increases threefold.66  
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4.3 Pathogenesis and incidence of abrupt vessel closure 
Coronary balloon dilatation leads to endothelial denudation, intimal fissuring, and medial 
penetration and extensive damage causes obstructive dissection or intramural hematoma. 
When subintimal structures are exposed to the blood, then activation of platelets and thrombin 
formation occur. Obstructive thrombus can be formed with or without medial dissection.  
An autopsy finding of patients who experienced abrupt closure within 30 days after balloon 
angioplasty revealed that over 50% have intimal/medial dissection flaps with or without 
thrombi. Cases presenting with pure thrombi without dissection was very rare.  
It has been reported that the incidence of abrupt closure due to balloon angioplasty or 
atherectomy is 2-13.5%. About two thirds of cases of abrupt closure arise inside the  
catheterization laboratory and the majority occurs within the first 6 h after angioplasty. 
After routine stent implantation had replaced balloon angioplasty, the incidence of abrupt 
closure was dramatically decreased. Proper deployment technique and supportive drugs 
such as dual antiplatelet therapy and heparin also contribute toward the lower incidence.     
4.4 Clinical manifestations of abrupt closure 
Before the stent era, the incidence of abrupt closure-related mortality, myocardial infarction, 
and emergency CABG were 5%, 45%, and 55% respectively. However, since bailout stenting 
had been introduced, the incidence of emergency CABG owing to abrupt closure was 
reported to be 0.8%. Long term prognosis of abrupt closure in related to the increase of 
restenosis, 2-year mortality, myocardial infarction, and CABG. Well known predictors of 
abrupt closure are in Table 4. 
 
           Unstable angina 
           Diabetes mellitus 
           Female gender 
           Advanced age 
           Intraluminal thrombus 
           ACC/AHA score 
           Lesion length ≥2 luminal diameters or >10 mm 
           Extensive proximal tortuosity 
           Bend point ≥45 degrees 
           Branch point 
           Other stenoses ≥50% in same vessel 
           Multivessel disease 
           Ostial right coronary artery 
           Degenerated saphenous vein grafts 
           “Inoperable” surgical status 
           Collaterals originating from target vessel 
           Preangioplasty stenosis 90-99% 
Table 4. Predictor of abrupt closure 
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4.5 Managements 
 
Fig. 4. Management algorithm of abrupt closure  
1. Initial management 
When acute chest pain is recognized, nitroglycerin 100-200mcg should be injected into the 
coronary artery. If activated clotting time is less than 250 sec, additional heparin should be 
injected. Before the stent era, a size-matched balloon was inflated for at least 5 min and 
sometimes perfusion balloon was used. Currently, bailout stenting is considered as the most 
effective tool for abrupt or threatened coronary closure. Additional balloon inflation can 
recover blood flow to normal. Because the effect of rescue abciximab has been reported in 
many clinical trials and since it reduces subacute thrombus formation, administration of 
glycoprotein IIb/IIIa inhibitors is recommended. 
2. Coronary artery bypass graft  
In cases of acute closure due to left main coronary artery injury or coronary artery 
perforation, installation of intra-aortic balloon counterpulsation is necessary and emergency 
coronary artery bypass grafting (CABG) should be considered. A long dissection which does 
not resolve with stenting also needs CABG. 
5. Stent thrombosis 
5.1 Definition 
Definitions of stent thrombosis (ST) range from “angiographically proven to “clinically 
suspected” ST with the inclusion of myocardial infarction involving the target vessel to 
unexplained death (within 30 days). Although the first definition has a well-defined 
mechanism limited to selected patients undergoing angiography at the time of ST, there is 
concern for underestimation of the true incidence of ST. On the other hand, the other 
www.intechopen.com
 
Coronary Interventions 
 
60
broader definitions include events potentially related to disease progression, life threatening 
arrhythmias, myocardial infarction of non-culprit lesions, and non-cardiac sudden death 
and therefore overestimate the true incidence. Accounting for these limitations, an academic 
research consortium (ARC) proposed a new standardised definition of ST (Table 5).67 It is 
based on 2 principles: level of certainty that ST is underlying mechanism of the adverse 
event and the time of the adverse event relative to the index procedure. 
ST can be classified based on the time of adverse event (Figure 5). Early ST refers to the first 
30 days after stent implantation and is further stratified into acute (<24 hours) and subacute 
(24 hours to 30 days). Late ST is time between 1 month and 1 year. Very late ST means 
beyond 1 year. The rationale of this classification is to account for different 
pathophysiological mechanisms that may be at work at various times.   
 
Definite ST 
Definite stent thrombosis is diagnosed when either angiographic or pathological 
confirmation is  present 
Angiographic confirmation of ST* 
The presence of a thrombus originating in the stent or in the segment 5 mm proximal  
to the stented region and at least one of the following criteria within a 48-h time 
window:  
     Acute onset of ischemic symptoms at rest (typical chest pain >20 min) 
     New ischemic ECG changes suggestive of acute ischemia 
     Typical rise and fall in cardiac biomarkers 
Pathological confirmation of stent thrombosis 
     Evidence of recent thrombus within the stent determined at autopsy 
Probable ST 
Clinical definition of probable ST is diagnosed after intracoronary stenting in the 
following cases 
Any unexplained death within the first 30 d 
Regardless of the time after the index procedure, any MI that is related to documented  
acute ischemia in the territory of the implanted stent without angiographic 
confirmation of ST and in the absence of any other obvious cause  
Possible ST 
Clinical definition of possible ST is diagnosed with any unexplained death from 30 d after 
intracoronary stenting until the end of trial follow-up  
*The incidental angiographic documentation of stent occlusion in the absence of clinical signs or 
symptoms (silent occlusion) is (for this purpose) not considered a confirmed stent thrombosis. 
Table 5. Definition of ST as Proposed by the Academic Research Consortium67 
www.intechopen.com
 
Complications of Coronary Intervention 
 
61 
 
Fig. 5. Classification based on the time frame of adverse events 
5.2 Incidence 
In the bare metal stent (BMS) era, most of ST was early ST and very late ST was extremely rare, 
although several cases of late ST were reported.73,74 Early ST is encountered with a similar or 
even somewhat lower frequency after drug-eluting stent (DES) compared with BMS. A meta-
analysis of 6 studies comparing BMS with sirolimus-eluting stent (SES) reported that early 
rates of ST were 0.5% with SES and 0.6% with BMS, respectively (P=0.55).68 A pooled analysis 
of 5 trials comparing BMS with paclitaxel-eluting stent (PES) revealed early ST was 0.5% in 
PES and 0.6% in BMS, respectively (P=0.51).69 Although there had been some reported cases of 
late ST during the BMS era, this was not a clinical concern for most. According to recent a 
meta-analysis, no differences existed in the incidence of late ST between DES and BMS (0.2% 
versus 0.3%, 95% CI: 0.35-2.84; P=1.00).70 In another meta-analysis of 9 trials comparing SES 
and PES, no significant differences were detected for up to 1 year of follow-up (Figure 6).93 
 
Fig. 6. Risk of ST in 9 trials directly comparing SES and PES with follow-up to 1 year.93 
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Case reports, observational studies, extended follow-up of trials comparing DES with BMS, 
and meta-analyses of randomized trials have corroborated that very late ST is more common 
with DES than BMS. Pooled analysis of 4 randomized trials comparing SES with BMS and 5 
randomized trials comparing PES with BMS revealed similar rates of late ST but 
significantly more very late ST (0.6% versus 0% for SES versus BMS, P=0.03; 0.7% versus 
0.2% for PES versus BMS, P=0.03).72  
5.3 Clinical sequelae  
The reason why ST attracts attention is that it is associated with much higher mortality 
compared to other complications. Moreover, ST may be responsible for late complications of 
MI, including heart failure, arrhythmias, or mechanical complications. The impact of ST 
depends upon the myocardial area at risk, its viability, the degree of instantly recruitable 
collaterals, and the availability of rapid reperfusion therapy. The mortality rate varies 
depending on the definition of ST and follow-up duration (7-45%).73-77 Most ST patients 
experience myocardial infarction (>66%) with no differences between DES and BMS.71  
5.4 Risk factors  
ST is a multifactorial problem related to the stent itself, procedural factors, response to 
antiplatelet drugs, and lesion factors (Table 6). Many cases of early ST are caused by the 
procedure itself such as the presence of residual dissections or stent underexpansion. Poor 
response to antiplatelet drugs is also a documented cause of ST.78 Individual or ethnic 
differences have been reported and it has been suggested that several genetic 
polymorphisms are related to this drug resistance. Discontinuation of antiplatelet drugs is 
one of the most important predictors of ST. Patients noncompliance is the main problem and 
discontinuation due to dental procedures, surgical procedures or bleeding is also an 
important predisposing factor for late and very late ST.76 
5.5 Pathogenesis 
1. Hypersensitivity reaction with extensive vasculitis 
Virmani and colleagues79 first described a case of local hypersensitivity reaction with 
extensive vasculitis of the intima, media, and adventitia consisting predominantly of 
lymphocytes and eosinophils in a patient suffering very late DES thrombosis. 
Histopathological analysis of an autopsy case revealed aneurysmal dilatation of the vessel 
wall within the stented segment with incomplete stent apposition and thick fibrin thrombus 
between the stent and the arterial wall. Most hypersensitivity cases reported to the Food and 
Drug administration after DES implantation were attributed to the DES itself, especially the 
polymer coating. 
2. Delayed healing and dysfunctional endothelialization 
Another possible explanation is delayed healing and endothelial dysfunction. Delayed 
healing manifested by persistent fibrin deposition and incomplete reendothelialization 
emerged as an important discriminator between BMS and DES.80 Physiological evidence of 
dysfunctional endothelium comes from studies assessing vasomotion 6 months after DES 
implantation.81,82 Through the use of bicycle exercise during coronary angiography, the 
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segment proximal and distal to DES showed paradoxical vasoconstriction, whereas BMS 
demonstrated normal vasodilatation. 
Patient factors 
    Thickness and robustness of neointimal stent coverage 
    Drug response/interactions 
    Gene polymorphism 
    Left ventricular function 
    Acute coronary syndrome 
    Renal failure 
    Diabetes mellitus 
Antithrombotic and anticoagulation therapy 
    Coagulation activity 
    Inhibition of platelet aggregation 
Procedural factors 
    Dissection 
    Incomplete stent apposition 
    Stent expansion 
Lesion factors 
    Vessel size 
    Lesion length 
    Thrombus 
    Plaque characteristics 
    Bifurcation 
Device factors 
    Stent surface 
    Drugs 
    Polymer 
Table 6. Multifactorial Origin of ST 
3. Incomplete stent apposition 
Incomplete stent apposition resulting from positive arterial remodeling or stent 
underexpansion, and penetration of the stent into a necrotic core leads to ST. 
5.6 Prevention 
1. Patient and lesion selection 
PCI is not essential in all angina patients. The COURAGE trial, a randomization study 
comparing PCI and medical therapy in carefully selected patients with stable angina, 
revealed that there were no significant differences in mortality, acute myocardial infarction, 
and rehospitalization for acute coronary syndrome.83 It is therefore appropriate to consider 
medical therapy to the initial treatment option in stable angina patients with relatively low 
risk. In determining of use of BMS or DES, the risk of restenosis, the probability of bleeding 
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or non-cardiac surgery, and the risk of late ST should be considered. The situations that BMS 
can be used are as follows. 
1. De novo lesions of native vessel 
2. Reference diameter >3.5mm 
3. Short,focal lesions 
4. Patients with no diabetes mellitus 
5. Non-ostial lesions 
The need for non-cardiac surgical procedures may arise after recent DES implantation. ST 
can arise after antiplatelet therapy withdrawal, especially within 12 months after PCI. In a 
study of 103 stent patients undergoing noncardiac surgery, an alarming 5% mortality rate 
and 45% complication rate were noted.84 It should be determined whether the surgical 
procedure can be postponed beyond 12 months after stenting or whether dual antiplatelet 
therapy can be maintained throughout the perioperative period. However if it is not 
possible to delay surgery beyond 12 months, balloon angioplasty or BMS implantation can 
be considered instead of DES implantation.  
2. Antiplatelet therapy 
The important of dual antiplatelet maintenance after PCI cannot be emphasized strongly 
enough. In a registry, 14% discontinued thienopyridine therapy within 30 days after 
discharge.85 Predictors of premature thienopyridine discontinuation were older age, lower 
socioeconomic status, preexisting cardiovascular disease, and lack of discharge instructions 
or cardiac rehabilitation referral. Mortality was about 10 times higher and rehospitalization 
was almost twice as high in patients without thienopyridine therapy. 
The optimal duration of dual antiplatelet therapy after DES implantation is not well 
established. 
The AHA/ACC guidelines are not based upon multicenter trials. Dual antiplatelet therapy 
is recommended at least 1 month for BMS implantation whereas for DES implantation, 
adherence to a 12 month regimen is recommended.86 It is also important that surgeons and 
dentists are advised not to automatically discontinue antiplatelet therapy but rather to 
consult first with the patient’s cardiologist. 
3. Technique 
Attention to technical details also may improve results when PCI is performed with DES. 
Optimal deployment of stents by full expansion throughout their entire length should be 
ensured and residual dissections should be avoided. Intravascular ultrasound or optical 
coherence tomography is helpful to avoid stent malapposition. Multiple stenting in 
bifurcation lesions should be limited to only cases where really needed.  
4. Development of new DES 
Because the polymer coatings of DES were suspected to be responsible for some of ST, 
biodegradable polymers87 and polymer-free DES88 were developed. Another approach 
banks on drugs with improved healing properties such as antibodies capturing CD34+ 
endothelial progenitor cells89 or antithrombotic substances90 applied to the stent surface. 
Biodegradable stents, fully disintegrated in the body over a long period of time, have been 
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recently  developed.91 The Titan-TINOX stent (Hexacath, Rueil-Malmaison, France) is made 
of stainless steel coated with a Titanium nitride oxide (TNO) compound. The coating 
minimizes the leakage of metal residues, mostly nickel, from the metal stent into the arterial 
wall and, to some extent, attenuates electrical conductivity. Thus, the device was designed 
to enhance endothelialization and decrease the rate of stent-related thrombosis and 
restenosis. Stent coating with TNO reduced angiographic and ultrasonic measures of 
restenosis compared with stainless steel control stents of otherwise identical design in the 
prospective, randomized, multicenter trial.92 
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